In our leaflet you will get an insight into the work of the Fraunhofer CIMD: We present the indication field of immune diseases, our bundled expertise, the path from the medical need to the new medications and our biobanks.
Development of a new drug must follow a multi-tiered process prescribed by legislation. It takes more than 13 years on average from the idea to the first market approval. The majority of this time is spent on studies to test the drug’s efficacy and tolerability and to determine the most appropriate administration protocol.
High-quality biomaterials are essential for conclusive, unbiased medical research findings. In the context of immune-mediated diseases, collection of such materials is often a limiting factor. The biobanks of Fraunhofer IME, Fraunhofer IZI, and Fraunhofer ITEM store, for example, blood, tissue, stool, and urine samples. These biomaterials can be used for research purposes whenever required.
Fraunhofer Cluster of Excellence Immune-Mediated Diseases